A new strategy to streamline vaccine development and oversight.
Oct 1, 2010
By:
Jill Wechsler
A new strategy to streamline vaccine development and oversight.
|
Too many REMS cause headaches for doctors and the industry.
Sep 1, 2010
By:
Jill Wechsler
Too many REMS cause headaches for doctors and the industry.
|
Plant closures, product recalls prompt FDA re-evaluation of GMP enforcement efforts.
Aug 1, 2010
By:
Jill Wechsler
Plant closures, product recalls prompt FDA re-evaluation of GMP enforcement efforts.
|
More information may be available on drug approvals, prices, and research to expand public understanding of regulatory policies.
Jul 1, 2010
By:
Jill Wechsler
More information may be available on drug approvals, prices, and research to expand public understanding of regulatory policies.
|
International outsourcing and rising theft spur regulatory action and manufacturer oversight.
Jun 1, 2010
By:
Jill Wechsler
International outsourcing and rising theft spur regulatory action and manufacturer oversight.
|
Broader benefits and biosimilars will offset hefty fees and discounts while preserving R&D incentives.
May 1, 2010
By:
Jill Wechsler
Broader benefits and biosimilars will offset hefty fees and discounts while preserving R&D incentives.
|
The FDA is expanding postmarketing safety requirements, despite limited resources to manage these added responsibilities.
Apr 1, 2010
By:
Jill Wechsler
The FDA is expanding postmarketing safety requirements, despite limited resources to manage these added responsibilities.
|
Mar 22, 2010
By:
Jill Wechsler
After months of increasingly rancorous debate, the House finally approved legislation March 21 that makes significant changes in the nation?s healthcare system.
|
The new Sentinel system aims to expand access to data on medical product safety and patient effects.
Mar 1, 2010
By:
Jill Wechsler
The new Sentinel system aims to expand access to data on medical product safety and patient effects.
|
|
